Latest Merck Kgaa Dm 5 (MKGAF) Headlines Merck KGaA

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Merck Kgaa Dm 5 (MKGAF) Headlines

Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.

Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents

Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.

Avanir Reports Wider Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 11, 8:37AM CST
Avanir reported 4Q13 net loss per share of 10 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents

Threshold Pharma's TH-302 in Melanoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 12:00PM CDT
Threshold Pharmaceuticals recently initiated a phase II trial on its pipeline candidate, TH-302.

Update on Threshold Pharma's TH-302 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 08, 10:20PM CDT
Threshold Pharma announced an amendment in the protocol for its pivotal phase III study of TH-302

Sanofi's Lemtrada Gets CHMP Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 01, 11:40AM CDT
The Committee for Medicinal Products for Human Use recommended the approval of Lemtrada

Data on Merck KGaA's L-BLP25 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 22, 9:00PM CDT
Merck KGaA presented detailed results on its oncology candidate L-BLP25, from the phase III study, START.

Merck KGaA Posts Higher Y/Y Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 15, 10:24AM CDT
Merck KGaA reported first quarter 2013 earnings per American Depository Receipt (ADR) of $2.79, up 28.1% year over year.

Merck KGaA-CBRX Renew Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 11, 3:00PM CDT
Merck KGaA and Columbia Labs renewed a license and supply agreement for Crinone (progesterone gel), extending it for an additional five years

Sanofi Reports Lemtrada Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 27, 4:30PM CDT
Sanofi's subsidiary, Genzyme, announced interim data on Lemtrada.

Merck KGaA-BMY Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 21, 4:15PM CDT
Merck KGaA announced a deal with Bristol-Myers Squibb for the promotion of different formulations of Glucophage (metformin hydrochloride) in China.

Merck KGaA - Nordic Bioscience Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 20, 4:00PM CDT
Merck KGaA recently announced a strategic deal with Nordic Bioscience Clinical Development A/S for its pipeline candidate, sprifermin.

Threshold Cuts Loss, Misses Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 13, 9:00AM CDT
Threshold Pharmaceuticals Inc. reported fourth-quarter 2012 net loss per share of 10 cents, narrower than the Zacks Consensus Estimate of a loss of 12 cents.

Strong Quarter for Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 08, 9:40AM CST
Merck KGaA reported fourth quarter 2012 earnings per American Depository Receipt of $2.66, up 18.8% year over year.

Positive Data from BMRN's PKU-016 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 20, 4:50PM CST
BioMarin announced positive results from the PKU-016 ASCEND study.

Threshold/Merck KGaA Drug in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 29, 4:15PM CST
Threshold Pharmaceuticals, Inc. and Merck KGaA announced the commencement of a global phase III study (MAESTRO) on their hypoxia-targeted candidate, TH-302.

FDA to Review Sanofi's Lemtrada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 29, 12:20PM CST
Sanofi announced that the FDA has accepted the marketing application of Lemtrada

Merck Kgaa Dm 5 (MKGAF) Stock Research Links

MKGAF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces Securities Lawsuit Amid Stock Dive

Updated Category News Views 80

Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...

Continue Reading
Mendocino Farms Faces Allegations Over Employee Practices

Updated Category News Views 8

Mendocino Farms Lands in Legal Hot Water Jobs pay the bills and keep the gears turning. But when a company like Mendocino Farms allegedly chucks out the rulebook, things get messy fast. We're talking about a hefty lawsuit aimed at this chain, accusing them of playing fast and loose with California's labor laws. If you've been around the block like me, you know that...

Continue Reading
Patriot Fund Gala Celebrates Veterans and America's 250th

Updated Category News Views 21

Celebrating Service and Patriotism in Philadelphia The Patriot Fund is gearing up for its 11th Annual Gala, a night dedicated to honoring the veterans who have sacrificed so much for this nation. Set against the historic backdrop of Philadelphia, the gala coincides with America's 250th anniversary—couldn't have picked a better time or place for such an event. It’s not...

Continue Reading
Zoomlion's Tower Cranes: Engineering Feats at Great Heights

Updated Category News Views 5

Pushing Boundaries with Towering Achievements When you're looking up at an engineering marvel, there's a good chance mighty cranes had their heyday lifting those towering ambitions. Zoomlion Heavy Industry Science & Technology Co., Ltd. just pulled a power move at the Lugu Lake Grand Bridge's 283-meter Shangri-La-side main tower. Picture that: two R4300-200 bad boys...

Continue Reading
Ruth, Mickey, Superman: Morphy's Auction Smorgasbord

Updated Category News Views 4

A Surreal Gathering of Icons and Memorabilia Who'd have thought you could snag both Babe Ruth and Mickey Mouse in one fell swoop? Well, come November 10-12, 2026, fans and collectors alike will have the opportunity at Morphy Auctions in Denver, PA. It's a dizzying array of Americana where cultural legend meets sports royalty, and we're not talking pocket change here. Babe...

Continue Reading
Callender Bowlin's Legal Eagles Soar in Texas 2026

Updated Category News Views 4

The Spotlight on CB Trial's Legal Titans Roll the dice, folks—who stands up in Texas’ legal playground? It's Callender Bowlin, PLLC's hotshots again securing their hallmark in the 2026 Texas Super Lawyers gauntlet. This ain’t their first rodeo, either. Founding partners Mark Callender and Josh Bowlin—names synonymous with high-stakes litigation—continue to bask...

Continue Reading
Vinitaly.USA 2026: Italian Wine Takes Manhattan

Updated Category News Views 11

A Two-Day Wine Extravaganza Hits New York If Italian wine was a stock, the Vinitaly.USA 2026 gathering in New York would be a rallying cry to double down. October 26-27 is set to be a whirl of handshakes and clinking glasses at Pier 36, all under the grand vision of beefing up Italy's hold on the U.S. wine market. As the compass points to growing opportunities, one can't...

Continue Reading
VoxNexus Debuts On-Device AI: A Game-Changer for Languages

Updated Category News Views 44

VoxNexus Changes the Game with VoxEdge Here's the rub with tech: it often feels like it's only for the folks who already have a leg up. VoxNexus just flipped the script with its new product, VoxEdge, an on-device voice stack that's making waves by breaking language barriers in the ever-evolving AI world. This move might just shift the landscape of voice artificial...

Continue Reading
Bidease Taps Moloco Veteran Dock Kim for Growth Role

Updated Category News Views 7

In the rough-and-tumble world of mobile advertising, cutting through the noise with real results is no easy feat. Yet Bidease finds itself riding high on a wave of growth—200% revenue increase over back-to-back years. That's no small potatoes, and now they're topping it off with a savvy hire: Dock Kim, the former revenue honcho at Moloco, is on deck as the new VP of...

Continue Reading
HumanView Relaunch: LEAP Group Decodes Customer Signals

Updated Category News Views 14

Understanding Customer Signals Like Never Before Well, here's one for the ol' playbook. The LEAP Group just dusted off their tool, HumanView, like an old car getting a fresh coat of paint and an engine overhaul. It's been rebuilt from the ground up, promising to turn those random blips of online chatter into actionable business insights. Not the same old dashboard mumbo...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Cybersecurity: NetSPI Launches EASM Solutions

Updated Category News Views 247

NetSPI Introduces External Attack Surface Management Solutions The NetSPI Platform presents innovative external attack surface management (EASM) solutions that provide ongoing discovery, inventory management, and testing of assets, exposures, and vulnerabilities. This comprehensive approach ensures organizations achieve greater depth, breadth, and significantly reduced...

Continue Reading
Investing Insights: 3 Tech Stocks to Watch for Growth

Updated Category News Views 236

Tech Stocks with Potential for Q4 Gains The technology sector often showcases incredible opportunities, especially for investors seeking undervalued companies. As we approach the end of the year, several stocks have caught the attention of analysts and investors alike. The Relative Strength Index (RSI) is a valuable momentum indicator that can signal whether a stock is...

Continue Reading
Understanding the Ongoing Impact of Tariff Uncertainty

Updated Category News Views 112

Understanding the Ongoing Impact of Tariff Uncertainty The recent inaction by the Supreme Court regarding tariffs imposed during President Donald Trump's administration has left investors pondering the implications on the market. The lack of a definitive ruling signifies that one of the most significant sources of market risk remains intact. This absence of clarity...

Continue Reading
Parker Barrile Joins Dave as New Chief Product Officer

Updated Category News Views 186

Parker Barrile Joins Dave as Chief Product Officer Los Angeles – In an exciting development for Dave Inc. (Nasdaq: DAVE), a prominent player in the neobank sector, Parker Barrile has been appointed as the Chief Product Officer. This strategic decision is set to take effect soon, marking a pivotal moment in the company’s growth story. Experience and Vision Parker...

Continue Reading
Transform Your Investment: The Power of Compounding with AEM

Updated Category News Views 145

The Journey of Agnico Eagle Mines Ltd Agnico Eagle Mines Limited (NYSE: AEM) is a well-respected player in the mining industry, known for its robust operational performance and strategic growth. Over the past two decades, it has consistently outperformed broader market indexes, showcasing an impressive annualized return rate of 11.8%. This remarkable performance has...

Continue Reading